The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro. Fatima N, Shen Y, Crassini K, Burling O, et al. Leuk Lymphoma 2024;65:585-597.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Fatima N, Shen Y, Crassini K, Burling O, et al. The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro. Leuk Lymphoma 2024;65:585-597.
PMID: 38227293